Coagulopathy of Acute Liver Failure

Clinics in Liver Disease

Volumn 13, Issue 1, 2009, Pages 95-107

  Munoz, Santiago J ^a,b   Stravitz, R Todd ^c   Gabriel, Don A ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Clotting; Coagulopathy; Factor VII; Fulminant; Hepatitis; Liver; Plasma

Indexed keywords

FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP; WARFARIN;

BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL EVALUATION; CLINICAL FEATURE; CRYOPRECIPITATE; DISEASE SEVERITY; HUMAN; LABORATORY TEST; LIVER FAILURE; LIVER TRANSPLANTATION; PATHOPHYSIOLOGY; PLASMAPHERESIS; PROTHROMBIN TIME; REVIEW; THROMBOCYTE TRANSFUSION;

BLOOD COAGULATION DISORDERS; DISEASE PROGRESSION; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; POSTOPERATIVE HEMORRHAGE;

EID: 55849141743     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2008.10.001     Document Type: Review

References (76)

1. Schiodt F., Atillasoy E., Shakil O., et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl 5 (1999) 29-34
2. Munoz S. Prothrombin time in fulminant hepatic failure. Gastroenterology 100 (1991) 1480-1489
3. Ostapowicz G., Fontana R., Schiedt F., et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137 (2002) 947-954
4. Trey C., and Davidson C.S. The management of fulminant hepatic failure. Prog Liver Dis 3 (1970) 282-298
5. O'Grady J.G., Langley P.G., Isola L., et al. Coagulopathy of fulminant hepatic failure. Semin Liver Dis 6 2 (1986) 159-163
6. Muñoz S.J. Difficult management problems in fulminant hepatic failure. Semin Liver Dis 13 4 (1993) 395-413
7. Anand A., Nightingale P., and Neuberger J. Early indicators of prognosis in fulminant hepatic failure: an assessment of the King's criteria. J Hepatol 26 (1997) 62-68
8. Munoz S., Reddy R., Lee W., et al. Coagulopathy in acute liver failure. Neurocrit Care 9 (2008) 103-107
9. Pereira S.P., Langley P.G., and Williams R. The management of abnormalities of hemostasis in acute liver failure. Semin Liver Dis 16 (1996) 403-414
10. Trotter J.F. Coagulation abnormalities in patients who have liver disease. Clin Liver Dis 10 (2006) 665-678
11. Cornillon B., Paul J., Belleville J., et al. Experimental DMNA induced hepatic necrosis: early course of haemostatic disorders in the rat. Comp Biochem Physiol 80 (1985) 277-284
12. Schmidt L.E., and Larsen F.S. MELD score as a predictor of liver failure and death in patients with acetaminophen-induced liver injury. Hepatology 45 (2007) 789-796
13. O'Grady J.G., Alexander G.J., Hayllar K.M., et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 97 (1989) 439-445
14. Bernuau J., and Benhamou J.P. Fulminant and subfulminant liver failure. In: Bircher J., Benhamou J.P., and McIntyre N. (Eds). Oxford textbook of clinical hepatology. 2nd edition (1999), Oxford University Press, Oxford (U.K.) 1341
15. Macdougall B.R., Bailey R.J., and Williams R. H2-receptor antagonists and antacids in the prevention of acute gastrointestinal haemorrhage in fulminant hepatic failure. Two controlled trials. Lancet 1 (1977) 617-619
16. Sherlock S. Fulminant hepatic failure. Adv Intern Med 38 (1993) 245-267
17. Clark R., Rake M.O., Flute P.T., et al. Coagulation abnormalities in acute liver failure: pathogenetic and therapeutic implications. Scand J Gastroenterol Suppl 19 (1973) 63-70
18. Gazzard B.G., Henderson J.M., and Williams R. Early changes in coagulation following a paracetamol overdose and a controlled trial of fresh frozen plasma therapy. Gut 16 (1975) 617-620
19. Gazzard B.G., Portmann B., Murray-Lyon I.M., et al. Causes of death in fulminant hepatic failure and relationship to quantitative histological assessment of parenchymal damage. QJM 44 (1975) 615-626
20. Boks A.L., Brommer E.J., Schalm S.W., et al. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology 6 (1986) 79-86
21. Lisman T., and Leebeek F.W. Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg 24 4 (2007) 250-258
22. Valla D., Flejou J.F., Lebrec D., et al. Portal hypertension and ascites in acute hepatitis: clinical, hemodynamic and histological correlations. Hepatology 10 (1989) 482-487
23. Lebrec D., Nouel O., Bernuau J., et al. Portal hypertension in fulminant viral hepatitis. Gut 21 (1980) 962-964
24. Macdougall B.R., and Williams R. H2-receptor antagonist in the prevention of acute upper gastrointestinal hemorrhage in fulminant hepatic failure: a controlled trial. Gastroenterology 74 2 Pt 2 (1978) 464-465
25. Stravitz R.T., Kramer A.H., Davern T., et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med 35 11 (2007) 2498-2508
26. Blei A.T., Olafsson S., Webster S., et al. Complications of intracranial pressure monitoring in fulminant hepatic failure. Lancet 16 341 (1993) 157-158
27. Vaquero J., Fontana R.J., Larson A.M., et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl 11 (2005) 1581-1589
28. Donaldson B.W., Gopinath R., Wanless I.R., et al. The role of transjugular liver biopsy in fulminant liver failure: relation to other prognostic indicators. Hepatology 18 (1993) 1370-1376
29. Hanau C., Munoz S., and Rubin R. Histopathological heterogeneity in fulminant hepatic failure. Hepatology 21 (1995) 345-351
30. Carlier M., Van Obbergh L.J., Veyckemans F., et al. Hemostasis in children undergoing liver transplantation. Semin Thromb Hemost 19 3 (1993) 218-222
31. Mor E., Jennings L., Gonwa T.A., et al. The impact of operative bleeding on outcome in transplantation of the liver. Surg Gynecol Obstet 176 (1993) 219-227
32. O'Grady J.G., Alexander G.J., Thick M., et al. Outcome of orthotopic liver transplantation in the aetiological and clinical variants of acute liver failure. Q J Med 68 (1988) 817-824
33. Bernal W., Wendon J., Rela M., et al. Use and outcome of liver transplantation in acetaminophen-induced acute liver failure. Hepatology 27 (1998) 1050-1055
34. Devlin J., Wendon J., Heaton N., et al. Pretransplantation clinical status and outcome of emergency transplantation for acute liver failure. Hepatology 21 (1995) 1018-1024
35. Farmer D.G., Anselmo D.M., Ghobrial R.M., et al. Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period. Ann Surg 237 (2003) 666-675
36. Lisman T., Leebeek F.W.G., and de Groot P.G. Haemostatic abnormalities in patients with liver disease. J Hepatol 37 (2002) 280-287
37. Lentschener C., Roche K., and Ozier Y. A review of aprotinin in orthotopic liver transplantation: can its harmful effects offset its beneficial effects?. Anesth Analg 100 (2005) 1248-1255
38. Kerr R., Newsome P., Germain L., et al. Effects of acute liver injury on blood coagulation. J Thromb Haemost 1 (2003) 754-759
39. Hughes R.D., Nicolaou N., Langley P.G., et al. Plasma cytokine levels and coagulation and complement activation during use of the extracorporeal liver assist device in acute liver failure. Artif Organs 22 (1998) 854-858
40. Scherer R., Gille A., Erhard J., et al. The effect of substitution with AT II- and PPSB- concentrates in patients with terminal lover insufficiency. Anaesthesist 43 (1994) 178-182
41. Langley P.G., Forbes A., Hughes R.D., et al. Thrombin-antithrombin III complex in fulminate hepatic failure: evidence for disseminated intravascular coagulation and relationship to outcome. Eur J Clin Invest 20 (1990) 627-631
42. Yamaguchi M., Gabazza E.C., Taguchi O., et al. Decreased protein C in patients with fulminant hepatic failure. Scand J Gastroenterol 41 (2006) 331-337
43. Ben-Ari Z., Osman E., Hutton R.A., et al. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction?. Am J Gastroenterol 94 (1999) 2977-2982
44. Hirata K., Ohata Y., and Fujiwara K. Hepatic sinusoidal cell destruction in the development of intravascular coagulation in acute liver failure of rats. J Pathol 158 (1989) 157-165
45. Mochida S., Arai M., Ohno A., et al. Deranged blood coagulation equilibrium as a factor of massive liver necrosis following endotoxin administration in partially hepatectomized rats. Hepatology 29 (1999) 1532-1540
46. Langley P.G., Hughes R.D., and Williams R. Increased factor VIII complex in fulminant hepatic failure. Thromb Haemost 54 (1985) 693-696
47. Kelly D.A., and Summerfield J.A. Hemostasis in liver disease. Semin Liver Dis 7 (1987) 182-191
48. Francis J.L. Acquired dysfibrinogenemia in liver disease. J Clin Pathol 35 (1982) 667-672
49. Green G., Thomson J.M., Dymock I.W., et al. Abnormal fibrin polymerization in liver disease. Br J Haematol 34 (1976) 427-439
50. Carr M.E., and Gabriel D.A. Altered plasma viscosity and shear dependent gelation of an IgM cryoglobulin. Clin Hemorheol 6 (1987) 529-540
51. Tripodi A., Salerno F., Chantarangkul V., et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 41 (2005) 553-558
52. Robert A., and Chazouilleres O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio?. Hepatology 24 (1996) 1392-1394 Ewe K.Dig Dis Dci 1981;26:973-93
53. Dillon J.F., Simpson J.K., and Hayes P.C. Liver biopsy bleeding time: an unpredictable event. J Gastroenterol Hepatol 9 (1994) 269-271
54. Caldwell S.H., Hoffman M., Lisman T., et al. Coagulation disorders and hemostasis in liver disease: pathology and critical assessment of current management. Hepatology 44 (2006) 1039-1046
55. Rappaport S. Coagulation problems in liver disease. Blood Coagul Fibrinolysis 11 Suppl 1 (2000) S69-S74
56. Amitrano L., Guardascione M.A., Brancaccio V., et al. Coagulation disorders in liver disease. Semin Liver Dis 22 (2002) 83-96
57. Boyadjian H.P. Prognostic significance of antithrombin III, plasminogen and proactivatios of plasminogen activity in viral hepatitis. Dtsch Z Verdau Stoffwechselkr 48 (1988) 83-93
58. Lisman T., Leebeek F.W., Mosier L.O., et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased fibrinolysis. Gastroenterology 121 (2001) 131-139
59. Okumoto K., Siato T., Onodera M., et al. Serum levels of stem cell factor and thrombopoietin are markedly decreased in fulminant hepatic failure patients with a poor prognosis. J Gastroenterol Hepatol 8 (2007) 1171-1173
60. Schiodt F.V., Balko J., Schilsky M.E., et al. Thrombopoietin in acute liver failure. Hepatology 37 (2003) 558-561
61. Pereira J., Accatino L., Alfaro J., et al. Platelet autoantibodies in patients with chronic liver disease. Am J Hematol 50 (1995) 173-178
62. Pockros P.J., Duchini A., McMillan R., et al. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol 97 (2002) 2040-2045
63. Escolar G., Cases A., Vinas M., et al. Evaluation of acquired platelet dysfunction in uremic and cirrhotic patients using the platelet analyzed PFQ100: influence of hematocrit elevation. Haematologica 84 (1999) 614-619
64. Laffi G., Cominelli F., Ruggiero M., et al. Altered platelet function in cirrhosis of the liver: impairment of inositol lipid and arachidonic acid metabolism in response to agonists. epatHhHH. Hepatology 8 (1988) 1620-1626
65. Ordinas A., Escolar G., Cirera, et al. Defective signal transduction in platelets from cirrhosis is associated with increased cyclic nucleotides. Gastroenterology 105 (1993) 148-156
66. Shami V., Caldwell S., and Hespenheide E. Recombinant activated factor VII for coagulopathy of fulminant hepatic failure compared with conventional therapy. Liver Transpl 9 (2003) 138-143
67. Quan D., Bass N., Hirose R., et al. The effect of recombinant factor VIIa and fresh frozen plasma on the INR in patients with acute and chronic liver failure. Hepatology 38 4 (2003) 550A
68. Porte R., and Caldwell S. The role of recombinant factor VIIa in liver transplantation. Liver Transpl 11 (2005) 872-874
69. Pavese P., Bonadona A., Beaubien J., et al. FVIIa corrects the coagulopathy of liver failure but may be associated with thrombosis: a report of four cases. Can J Anaesth 52 (2005) 26-29
70. Munoz S., Ballas S., Moritz M., et al. Perioperative management of fulminant and subfulminant liver failure with therapeutic plasmapheresis. Transplant Proc 21 (1989) 3535-3536
71. Takahashi T., Malchesky P., and Nose Y. Artificial liver: state of the art. Dig Dis Sci 36 (1991) 1327-1340
72. Akamatsu K., Tanaka Y., Tada K., et al. Filtration of fresh frozen plasma used as substitution fluid in plasma exchange in order to remove microaggregates. Artif Organs 14 (1990) 429-435
73. Takahashi Y., and Shimizu M. Aetiology and prognosis of fulminant viral hepatitis in Japan: a multicentre study. J Gastroenterol Hepatol 6 (1991) 159-164
74. Gazzard B., Clark R., Borirakchanyavat V., et al. A controlled trial of heparin therapy in the coagulation defect of paracetamol-induced hepatic necrosis. Gut 15 (1974) 89-93
75. Pereira S., Rowbotham D., Fitt S., et al. Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease. J Hepatol 42 (2005) 365-370
76. Reverter J.C. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? Yes. J Thromb Haemost 4 (2006) 717-720